Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00219817 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss
A Phase 2 study, sponsored by Helsinn Therapeutics (U.S.).
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT00219817: Completed Phase 2 study, sponsored by Helsinn Therapeutics (U.S.).
NCT00219817 is a Phase 2 study that has completed, run by Helsinn Therapeutics (U.S.). The registered enrollment target is 80 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00219817, a Phase 2 study, has completed, sponsored by Helsinn Therapeutics (U.S.).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
Anorexia and weight loss are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients. Activation of Ghrelin receptors have been demonstrated to stimulate appetite. RC-1291 HCl, by virtue of its ghrelin like activity and Growth Hormone releasing effects may have a dual role in the reversal of cancer induced anorexia and weight loss. This study will test the safety and efficacy of RC-1291 in the treatment of cancer patients with anorexia and weight loss.
Interventions
- DRUG RC-1291 HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2005-06 |
| Est. Completion | 2006-10 |
| Phase | Phase 2 |
What the finished NCT00219817 record still lists
NCT00219817 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 1 intervention - of which RC-1291 HCl is the first listed.
NCT00219817 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00219817 about?
NCT00219817 is a clinical study titled "Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss". Anorexia and weight loss are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients. Activation of Ghrelin receptors have been demonstrated to stimulate appetite. RC-1291 HCl, by virtue of its ghrelin like activity and Growth Hormone relea...
What is the current status of trial NCT00219817?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2005-06. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00219817?
The interventions under investigation include: RC-1291 HCl (DRUG).
Who is sponsoring clinical trial NCT00219817?
This trial is sponsored by Helsinn Therapeutics (U.S.), which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00219817's enrollment target sits among peer trials
80 842nd of 2000 higher than 1,117 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia